tremelimumab,savolitinib,durvalumab
hutchmed,pfizer,astrazeneca,orpathys
['savolitinib', 'calypso', 'tremelimumab', 'durvalumab', 'rcc,(-irccs),(-srcc),(-urcc)']
#asco22 presenting the results of the phase 2 calypso trial of durvalumab +/- savolitinib or tremelimumab in patients with mrcc, along with associated molecular analyses 
Director, @danaFarber_GU & International Strategic Initiatives @DanaFarber. Kohlberg Prof. of Medicine @Harvardmed. @PanMass rider. #SoccerIsLife. Views Mine.